The third quarter proved less grim for the life science industry, with investors finally showing some confidence in drugmakers and other public firms in the space.
Public and media criticism over high drug prices — and the political uncertainty over whether drugmakers will face some sort of crackdown — has put a damper on drugmakers’ stock performance for the past 12 months.
In the third quarter, however, the Nasdaq Biotech Index (NBI) showed a 10 percent bump in performance.
The San Diego Business Journal compared nearly 30 local life science firms with the NBI, and found the local sector is also up — having climbed 6.33 percent from July to September.
Which San Diego firms had the most extreme ups and downs during this (finally) bullish time?
Here’s a quick look at the biggest winners and losers in the third quarter of 2016.